

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT BY APPLICANT		ATTY. DOCKET NO. 102108-300		SERIAL NO. 10/765580		
		APPLICANT: MARINA V. BACKER, ET AL.				
		FILING DATE: HERewith		GROUP: 1649		
U.S. PATENT DOCUMENTS						
EXAMINER INITIAL*	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROP.
RH	6,037,329	March 14, 2000	Baird, et al.	514	44	Sept. 24, 1996
RH	6,036,955	3/14/01	Thorpe et al.	424	136.1	June 7, 1995
FOREIGN PATENT DOCUMENTS						
	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION Yes No
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)						
1. RH	"Hypoxic Regulation of Vascular Endothelial Growth Factor in Retinal Cells", (Aiello et al.) <i>Arch/Ophthalmol.</i> , Vol. 113, pp. 1538-1544, 1995.					
2.	"Cytotoxicity of a Shiga Toxin A Subunit-CD4 Fusion Protein to Human Immunodeficiency Virus-Infected Cells, (Al-Jauby et al.) <i>Infection and Immunity</i> , Vol. 62, No. 3, pp. 956-960, 1994.					
3.	"Purification and Characterization of a Shiga Toxin A Subunit-CD4 Fusion Protein Cytotoxic to Humman Immunodeficiency Virus-Infected Cells" (Al-Jauby et al.) <i>Infection and Immunity</i> , Vol. 63, No. 8, pp. 3073-3078, 1995.					
4.	"Vascular Endothelial Growth Factor Chimeric Toxin Is Highly Active against Endothelial Cells", Arora et al., <i>Cancer Research</i> , Vol. 59, pp. 183-188, 1999.					
5.	"Molecular and Cellular Cardiology/Gene Transfer: Accelerated Restitution of Endothelial Integrity and Endothelium-Dependent Function After pvVEGF sub 165 Gene Transfer", Takayuki et al., <i>Ovid: Ashara: Circulation</i> , Vol. 94 (12), pp. 3291-3302, 1996.					
6.	"Interaction of Vasculotropin/Vascular Endothelial Cell Growth Factor With Human Umbilical Vein Endothelial Cells: Binding, Internalization, Degradation, and Biological Effects" Bikfalvi et al., <i>Journal of Cellular Physiology</i> , Vol. 149, pp. 50-59, 1991.					
7. ↓	"Increased Expression of Vascular Permeability Factor (Vascular Endothelial Growth Factor) and Its Receptors in Kidney and Bladder Carcinomas" (Brown et al.) <i>American Journal of Pathology</i> , Vol. 143, No. 5, pp. 1255-1262, 1993.					

Note that the authors should be cited first

8.	RH	"Expression of Vascular Permeability Factor (Vascular Endothelial Growth Factor) and Its Receptors in Breast Cancer" <u>Brown et al.</u> , <i>Human Pathology</i> , Vol. 26, pp. 86-91, No. 1, 1995.
9.		"Construction of Mutant Genes for a Non-Toxic Verotoxin 2 Variant (VT2vp1) of <i>Escherichia coli</i> and Characterization of Purified Mutant Toxins" <u>Cao et al.</u> , <i>Microbiol. Immunol.</i> , 38(6), pp. 441-447, 1994.
10.		"Regulation of VEGF/VPF expression in tumor cells: Consequences for tumor growth and metastasis" <u>Claffey et al.</u> , <i>Cancer and Metastasis Review</i> , 15, pp. 165-176, 1996.
11.		"Vascular Endothelial Growth Factor/Vascular Permeability Factor (VEGF/VPF) in Normal and Atherosclerotic Human Arteries" <u>Couffinhal et al.</u> , <i>American Journal of Biology</i> , Vol. 150, No. 5, pp. 1673-1685, 1997.
12.		"The role of tyrosine-114 in the enzymatic activity of the Shiga-like toxin-1 A-chain", <u>Deresiewicz et al.</u> , <i>Mol. Gen. Genet</i> , Vol. 241, pp. 467-473, 1993.
13.		"Overexpression of Vascular Permeability Factor/ Vascular Endothelial Growth Factor and its Receptors in Psoriasis" <u>Detmar et al.</u> , <i>J. Exp. Med.</i> , Vol. 180, pp. 1141-1146, 1994.
14.		"Angiogenesis" <u>Folkman et al.</u> , <i>The Journal of Biological Chemistry</i> , Vol. 267, No. 16, pp. 10931-10934, 1992.
15.		"Angiogenesis in cancer, vascular, rheumatoid and other disease", <u>Folkman</u> , <i>Nature Medicine</i> , Vol. 1, pp. 27-31, 1995.
16.		"Minimum Domain of the Shiga Toxin A Subunit Required for Enzymatic Activity", <u>Haddad et al.</u> , <i>Journal of Bacteriology</i> , Vol. 175, No. 16, pp. 4970-4978, 1993.
17.		"Signaling Vascular Morphogenesis and Maintenance" <u>Hanahan</u> , <i>Science</i> , Vol. 277(5322), pp. 48-50, 1997.
18.		"Ribotoxic Stress Response: Activation of the Stress-Activated Protein Kinase NK1 by Inhibitors of the Peptidyl Transferase Reaction and by Sequence-Specific RNA Damage to the α -Sarcin/Ricin Loop in the 28S rRNA" <u>Jordanov et al.</u> , <i>Molecular and Cellular Biology</i> , Vol. 17, No. 6, pp. 3373-3381, 1997.
19.		"Recent advances in understanding the pathogenesis of the hemolytic uremic syndromes", <u>Kaplan et al.</u> , <i>Pediatric Nephrology</i> , Vol. 4, pp. 276-283, 1990.
20.		"Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth <i>in vivo</i> " <u>Kim et al.</u> , <i>Nature</i> , Vol. 362, pp. 841-844, 1993.
21.	↓	"Glioblastoma growth inhibited <i>in vivo</i> by a dominant-negative Flk-1 mutant" <u>Millauer et al.</u> , <i>Nature</i> , Vol. 367, pp. 576-579, 1994.

Note that the authors should be cited first

22.	RH	"Vascular Endothelial Growth Factor And Its Receptors", Neufeld et al., <i>Progress in Growth Factor Research</i> , Vol. 5, pp. 89-97, 1994.
23.		"Vascular endothelial growth factor (VEGF) and its receptors", Neufeld et al., <i>The FASEB Journal</i> , Vol. 13, pp. 9-22, 1999.
24.		"Targeting The Tumor Vasculature: Inhibition Of Tumor Growth By A Vascular Endothelial Growth Factor-Toxin Conjugate", Olson et al., <i>Int. J. Cancer</i> , Vol. 73, pp. 865-870, 1997.
25.		"Endothelial Heterogeneity in Shiga Toxin Receptors and Responses", Obrig et al., <i>The Journal of Biological Chemistry</i> , Vol. 268, No. 21, pp. 15484-15488, 1993.
26.		"Pathogenesis of Haemolytic Uraemic Syndrome", Obrig et al., <i>The Lancet</i> , p. 687, September 1987.
27.		"Up-Regulation of Vascular Endothelial Growth Factor and Its Cognate Receptors in a Rat Glioma Model of Tumor Angiogenesis", Plate et al., <i>Cancer Research</i> , Vol. 53, pp. 5822-5827, 1993.
28.		"Vascular Endothelial Growth Factor-Toxin Conjugate Specifically Inhibits KDR/Flk-1-positive Endothelial Cell Proliferation <i>in Vitro</i> and Angiogenesis <i>in Vivo</i> ", Ramakrishnan et al., <i>Cancer Research</i> , Vol. 56, pp. 1324-1330, 1996.
39.		"The Histopathology of the Hemolytic Uremic Syndrome Associated with Verocytotoxin-Producing <i>Escherichia coli</i> infections", Richardson et al., <i>Human Pathology</i> , Vol. 19, No. 9, pp. 1103-1108, 1988.
30.		"Inhibition of Growth of C6 Glioma Cells <i>in Vivo</i> by Expression of Antisense Vascular Endothelial Growth Factor Sequence", Saleh et al., <i>Cancer Research</i> , Vol. 56, pp. 393-401, 1996.
31.		"Shiga Toxin, Shig-like Toxin II Variant, and Ricin Are All Single-site RNA N-Glycosidases of 28 S RNA When Microinjected into <i>Xenopus</i> Oocytes", Saxena et al., <i>The Journal of Biological Chemistry</i> , Vol. 264, No. 1, pp. 596-601, 1989.
32.		"Biological properties of VEGF/VPF receptors", Terman et al., <i>Cancer and Metastasis Reviews</i> , Vol. 15, pp. 159-163, 1996.
33.		"Renal dysfunction accounts for the dose limiting toxicity of DT ₃₉₀ anti-CD#sFv, a potential new recombinant anti-GVHD immunotoxin", Vallera et al., <i>Protein Engineering</i> , Vol. 10, No. 9, pp. 1071-1076, 1997.
34.		"VEGFs, receptors and angiogenesis", Veikkola et al., <i>Cancer Biology</i> , Vol. 9, pp. 211-220, 1999.
35.		"THE RNA-N-GLYCOSIDASE ACTIVITY OF SHIGA-LIKE TOXIN I: KINETIC PARAMETERS OF THE NATIVE AND ACTIVATED TOXIN", Brigotti et al., <i>Toxicom</i> , Vol. 35, No. 9, pp. 1431-1437, 1997.
36.		M. V. Backer, et al., "Engineering S-protein fragments of bovine ribonuclease A for targeted drug delivery", <i>National Library of Medicine</i> , Vol. 26, No. 3, pp. 455-461, 2002.
37.		M. V. Backer, et al., "Targeting endothelial cells overexpressing VEGFR-2: selective toxicity of Shiga-like toxin-VEGF fusion proteins", <i>National Library of Medicine</i> , Vol. 12, No. 6, pp. 1066-1073, 2001.
38.	✓	M. V. Backer, et al., "Shiga-like toxin-VEGF fusion proteins are selectively cytotoxic to endothelial cells overexpressing VEGFR-2," <i>National Library of Medicine</i> , Vol. 74, No. 1-3, pp. 349-355, 2001.
EXAMINER:		/Robert Hayes/
DATE CONSIDERED:		01/29/2007
<p>*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>		

\\14290\2\447215.1

Note that the authors should be cited first